Hard to Treat Diseases (Hard to Treat Diseases) EV-to-EBIT : (As of Jun. 20, 2024)

View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hard to Treat Diseases's Enterprise Value is $0.00 Mil. Hard to Treat Diseases does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Hard to Treat Diseases's EV-to-EBIT at this moment.

The historical rank and industry rank for Hard to Treat Diseases's EV-to-EBIT or its related term are showing as below:

HTDS's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.975
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hard to Treat Diseases's Enterprise Value for the quarter that ended in . 20 was $0.00 Mil. Hard to Treat Diseases does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Hard to Treat Diseases's Earnings Yield (Joel Greenblatt) % at this moment.

Hard to Treat Diseases EV-to-EBIT Historical Data

The historical data trend for Hard to Treat Diseases's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases EV-to-EBIT Chart

Hard to Treat Diseases Annual Data

Trend

EV-to-EBIT

Hard to Treat Diseases Quarterly Data

EV-to-EBIT

Competitive Comparison of Hard to Treat Diseases's EV-to-EBIT

For the Biotechnology subindustry, Hard to Treat Diseases's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hard to Treat Diseases's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's EV-to-EBIT falls into.

Hard to Treat Diseases EV-to-EBIT Calculation

Hard to Treat Diseases's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/
	=

Hard to Treat Diseases (OTCPK:HTDS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hard to Treat Diseases's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 )	=	EBIT	/	Enterprise Value (Q: . 20 )
	=		/
	=	%

Hard to Treat Diseases EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hard to Treat Diseases (Hard to Treat Diseases) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762

Website

http://www.htdsmedical.com

Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases (Hard to Treat Diseases) Headlines

No Headlines